Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Scios Nova Inc.
Stone downgraded the Mountain View, Calif., company to "underperform" with a fair value of $3-$4 after Auriculin failed to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury